RhumbLine Advisers
QTTB icon

RhumbLine Advisers’s Q32 Bio QTTB Stock Holding History

RhumbLine Advisers’s Portfolio QTTB Stock Details QTTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,156
Closed -$18.4K – 4287
2025
Q1 		$18.4K Sell
11,156
-94,388
-89% -$254K ﹤0.01% 3753
2024
Q4 		$363K Buy
105,544
+97,196
+1,164% +$3.07M ﹤0.01% 2876
2024
Q3 		$372K Buy
8,348
+690
+9% +$25.4K ﹤0.01% 2904
2024
Q2 		$137K Buy
7,658
+7,593
+11,682% +$182K ﹤0.01% 3404
2024
Q1 		$1.11K Hold
65
– – ﹤0.01% 4139
2023
Q4 		$713 Hold
65
– – ﹤0.01% 4179
2023
Q3 		$1.37K Hold
65
– – ﹤0.01% 4153
2023
Q2 		$1.04K Buy
+65
New +$1.17K ﹤0.01% 4285
2022
Q2 		– Sell
-3,151
Closed -$172K – 3254
2022
Q1 		$172K Sell
3,151
-190
-6% -$11.8K ﹤0.01% 2791
2021
Q4 		$219K Buy
3,341
+7
+0.2% +$679 ﹤0.01% 2811
2021
Q3 		$472K Buy
3,334
+47
+1% +$5.99K ﹤0.01% 2573
2021
Q2 		$430K Buy
3,287
+1,215
+59% +$152K ﹤0.01% 2635
2021
Q1 		$351K Sell
2,072
-192
-8% -$40.4K ﹤0.01% 2641
2020
Q4 		$460K Buy
2,264
+158
+8% +$30.5K ﹤0.01% 2476
2020
Q3 		$406K Sell
2,106
-275
-12% -$61.6K ﹤0.01% 2384
2020
Q2 		$651K Buy
2,381
+767
+48% +$204K ﹤0.01% 2226
2020
Q1 		$451K Buy
1,614
+15
+0.9% +$4.59K ﹤0.01% 2209
2019
Q4 		$596K Buy
1,599
+16
+1% +$4.58K ﹤0.01% 2291
2019
Q3 		$516K Buy
1,583
+65
+4% +$22.1K ﹤0.01% 2311
2019
Q2 		$535K Buy
1,518
+357
+31% +$140K ﹤0.01% 2333
2019
Q1 		$580K Sell
1,161
-20
-2% -$8.94K ﹤0.01% 2264
2018
Q4 		$475K Buy
1,181
+683
+137% +$258K ﹤0.01% 2319
2018
Q3 		$205K Buy
+498
New +$169K ﹤0.01% 2718

Other funds holding QTTB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RhumbLine Advisers's QTTB Position: Q2 2025 in Review

RhumbLine Advisers sold out of Q32 Bio (QTTB) in Q2 2025, closing a stake of 11,156 shares — an estimated $18.4K sold.

RhumbLine Advisers first reported a position in QTTB in Q3 2018 and held it in 23 quarters. The position peaked at $651K in Q2 2020. 61 funds tracked by Wall St. Rank hold QTTB as of Q2 2025.

  • RhumbLine Advisers reported no remaining Q32 Bio position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 11,156 Q32 Bio shares in Q2 2025, an estimated $18.4K.
  • RhumbLine Advisers first reported a position in Q32 Bio in Q3 2018 and held it in 23 quarters.
  • RhumbLine Advisers's Q32 Bio position peaked at $651K in Q2 2020.
  • 61 funds tracked by Wall St. Rank held Q32 Bio as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.